Opioid Withdrawal Syndrome (OWS)

Opioid Withdrawal Syndrome (OWS)

Opioid Withdrawal Syndrome is a condition that arises when individuals who are physically dependent on opioids either abruptly stop or significantly reduce their use. This leads to a spectrum of distressing physical and psychological symptoms, including anxiety, muscle pain, sweating, nausea, and sleep disturbances. The intensity and duration of withdrawal vary depending on the type of opioid, duration of use, and individual dependency levels. Standard treatment approaches involve the use of medications such as methadone, buprenorphine, and clonidine, which help manage symptoms. Psychological support, particularly cognitive-behavioral therapy (CBT), is also crucial for long-term recovery.

The growing awareness of opioid use disorder (OUD) and the broader opioid crisis have contributed to increased demand for effective OWS therapies. However, the treatment landscape faces barriers such as limited therapeutic options, social stigma, high treatment costs, and regulatory challenges. Addressing OWS effectively is a key part of the strategy to combat opioid addiction and improve public health outcomes.

Understanding starts here—check out the infographic for key insights

https://www.delveinsight.com/infographics/opioid-withdrawal-syndrome-market?utm_source=infographics&utm_medium=promotion&utm_campaign=akpr 

Epidemiological Segmentation (2020–2034)

OWS epidemiology in the 7 major markets (7MM) includes:

• Number of opioid misuse cases

• Number of individuals with chronic opioid use

• Total cases diagnosed with Opioid Withdrawal Syndrome
  
  

OWS Epidemiology (2022 Snapshot)

• Across the 7MM, an estimated 9 million individuals were engaged in long-term opioid use in 2022.

• In the U.S., approximately 7 million people experienced opioid withdrawal in 2022, with projections indicating a gradual decline over the forecast period.

• Within the EU4 and the UK, around 1.3 million cases of opioid misuse were recorded in 2022.
  
  

OWS Market Overview

• The market for Opioid Withdrawal Syndrome treatments in the 7MM was valued at around USD 1.3 billion in 2022.
  
  

From insights to impact—read the full report now : Click Here

Market Growth Drivers

• Rising recognition of opioid dependency as a serious health issue is increasing demand for treatment.

• The ongoing opioid epidemic continues to fuel the need for effective withdrawal management.

• Development of new pharmacological and behavioral treatments is broadening therapeutic choices.

• Governmental and private sector investments are expanding access to treatment options.
  
  

Market Challenges

• A lack of universal, highly effective treatments makes management inconsistent.

• Stigma around addiction often prevents people from seeking medical help.

• High costs of medications and behavioral therapies limit access, especially for underserved populations.

• Lengthy regulatory processes delay the availability of promising new therapies.
  
  

Get a snapshot of the 7MM landscape—view the infographic now : Click Here

Promising Pipeline Therapies

Emerging medications include:

• LUCEMYRA (lofexidine hydrochloride)

• BRIXADI / BUVIDAL

• PROBUPHINE / SIXMO

• And others in development
  
  

Leading Companies in the OWS Market

Key players developing and marketing OWS treatments:

• DemeRx IB, Inc.

• atai Life Sciences

• MediciNova

• BioXcel Therapeutics Inc.

• Titan Pharmaceuticals / Molteni Farmaceutici

• Braeburn Pharmaceuticals / Camurus

• US WorldMeds LLC

• Among others

Numbers tell part of the story—get the full analysis in our report

https://www.delveinsight.com/report-store/opioid-withdrawal-syndrome-market?utm_source=infographics&utm_medium=promotion&utm_campaign=akpr